Compare Biogen Inc (BIIB) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs GoPro Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while GoPro Inc trades at $0.7 (market cap $120.72M). The key difference: Biogen Inc is far larger — about 234.8× GoPro Inc's market cap, and Biogen Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | GPRO | |
|---|---|---|
Market Cap | $28.34B | $120.72M |
Sector | Health | Technology |
52-Week High | $216.63 | $2.88 |
52-Week Low | $122.68 | $0.64 |
Enterprise Value | $30.62B | $168.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
GoPro (GPRO) trades at $0.711, down 6.79% on the day, reflecting persistent operational challenges and negative investor sentiment. The stock exhibits a bearish technical outlook with consecutive earnings misses, declining revenue from $1.1B in 2022 to $652M in 2025, and negative net income margins. Recent news highlights a strategic review for potential sale or merger amid financial distress, including a $20M financing injection from CEO Nicholas Woodman in July 2026 to bolster liquidity.
The investment outlook remains highly speculative, with opportunities tied to a potential strategic transaction offering upside, but severe risks include going-concern warnings, cash burn, and competitive pressures. Analyst consensus is cautious, with only 21% buy ratings, emphasizing the binary nature of outcomes based on the company's ability to secure a lifeline or execute a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
